Small-molecule flunarizine increases SMN protein in nuclear Cajal bodies and motor function in a mouse model of spinal muscular atrophy

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 2045-2322

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Small-molecule flunarizine increases SMN protein in nuclear Cajal bodies and motor function in a mouse model of spinal muscular atrophy ; volume:8 ; number:1 ; day:1 ; month:2 ; year:2018 ; pages:1-17 ; date:12.2018
Scientific reports ; 8, Heft 1 (1.2.2018), 1-17, 12.2018

Creator: Sapaly, Delphine

Contributor: Dos Santos, Matthieu
Delers, Perrine
Biondi, Olivier
Quérol, Gwendoline
Houdebine, Léo
Khoobarry, Kevinee
Girardet, François
Burlet, Philippe
Armand, Anne-Sophie
Chanoine, Christophe
Bureau, Jean-François
Charbonnier, Frédéric
Lefebvre, Suzie
SpringerLink (Online service)

DOI: 10.1038/s41598-018-20219-1

URN: urn:nbn:de:1111-2018041618007

Rights: Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:49 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Sapaly, Delphine
Dos Santos, Matthieu
Delers, Perrine
Biondi, Olivier
Quérol, Gwendoline
Houdebine, Léo
Khoobarry, Kevinee
Girardet, François
Burlet, Philippe
Armand, Anne-Sophie
Chanoine, Christophe
Bureau, Jean-François
Charbonnier, Frédéric
Lefebvre, Suzie
SpringerLink (Online service)

Other Objects (12)

SMN deficiency perturbs monoamine neurotransmitter metabolism in spinal muscular atrophy

Understanding how SMN protein regulates the autophagy-lysosome pathway in spinal muscular atrophy

Posttranslational modifications of the Spinal Muscular Atrophy gene product SMN : Implications for therapy and pathophysiology

Recombinant SMN protein synergizes with spinal muscular atrophy therapy to counteract pathological motor neuron phenotypes

Spinal muscular atrophy

Enhancement of SMN protein levels in a mouse model of spinal muscular atrophy using novel drug‐like compounds

Calpain Inhibition Increases SMN Protein in Spinal Cord Motoneurons and Ameliorates the Spinal Muscular Atrophy Phenotype in Mice

The prevalence of SMN gene deletion/duplication in spinal muscular atrophy families referred to neuro-genetic centers of Mashhad, Iran

Graffiti | Streetart

SMN

Absence of gemin5 from SMN complexes in nuclear Cajal bodies

VPAC2 receptor agonist BAY 55-9837 increases SMN protein levels and moderates disease phenotype in severe spinal muscular atrophy mouse models

Muscle contractility in spinobulbar muscular atrophy

SMN deficiency perturbs monoamine neurotransmitter metabolism in spinal muscular atrophy

Understanding how SMN protein regulates the autophagy-lysosome pathway in spinal muscular atrophy

Posttranslational modifications of the Spinal Muscular Atrophy gene product SMN : Implications for therapy and pathophysiology

Recombinant SMN protein synergizes with spinal muscular atrophy therapy to counteract pathological motor neuron phenotypes

Spinal muscular atrophy

Enhancement of SMN protein levels in a mouse model of spinal muscular atrophy using novel drug‐like compounds

Calpain Inhibition Increases SMN Protein in Spinal Cord Motoneurons and Ameliorates the Spinal Muscular Atrophy Phenotype in Mice

The prevalence of SMN gene deletion/duplication in spinal muscular atrophy families referred to neuro-genetic centers of Mashhad, Iran

Graffiti | Streetart

SMN

Absence of gemin5 from SMN complexes in nuclear Cajal bodies

VPAC2 receptor agonist BAY 55-9837 increases SMN protein levels and moderates disease phenotype in severe spinal muscular atrophy mouse models

Muscle contractility in spinobulbar muscular atrophy

SMN deficiency perturbs monoamine neurotransmitter metabolism in spinal muscular atrophy

Understanding how SMN protein regulates the autophagy-lysosome pathway in spinal muscular atrophy

Posttranslational modifications of the Spinal Muscular Atrophy gene product SMN : Implications for therapy and pathophysiology

Recombinant SMN protein synergizes with spinal muscular atrophy therapy to counteract pathological motor neuron phenotypes

Spinal muscular atrophy

Enhancement of SMN protein levels in a mouse model of spinal muscular atrophy using novel drug‐like compounds

Calpain Inhibition Increases SMN Protein in Spinal Cord Motoneurons and Ameliorates the Spinal Muscular Atrophy Phenotype in Mice

The prevalence of SMN gene deletion/duplication in spinal muscular atrophy families referred to neuro-genetic centers of Mashhad, Iran

Graffiti | Streetart

SMN

Absence of gemin5 from SMN complexes in nuclear Cajal bodies

VPAC2 receptor agonist BAY 55-9837 increases SMN protein levels and moderates disease phenotype in severe spinal muscular atrophy mouse models

Muscle contractility in spinobulbar muscular atrophy

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Small-molecule flunarizine increases SMN protein in nuclear Cajal bodies and motor function in a mouse model of spinal muscular atrophy

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

SMN deficiency perturbs monoamine neurotransmitter metabolism in spinal muscular atrophy

Understanding how SMN protein regulates the autophagy-lysosome pathway in spinal muscular atrophy

Posttranslational modifications of the Spinal Muscular Atrophy gene product SMN : Implications for therapy and pathophysiology

Recombinant SMN protein synergizes with spinal muscular atrophy therapy to counteract pathological motor neuron phenotypes

Spinal muscular atrophy

Enhancement of SMN protein levels in a mouse model of spinal muscular atrophy using novel drug‐like compounds

Calpain Inhibition Increases SMN Protein in Spinal Cord Motoneurons and Ameliorates the Spinal Muscular Atrophy Phenotype in Mice

The prevalence of SMN gene deletion/duplication in spinal muscular atrophy families referred to neuro-genetic centers of Mashhad, Iran

SMN

Absence of gemin5 from SMN complexes in nuclear Cajal bodies

VPAC2 receptor agonist BAY 55-9837 increases SMN protein levels and moderates disease phenotype in severe spinal muscular atrophy mouse models

Muscle contractility in spinobulbar muscular atrophy

SMN deficiency perturbs monoamine neurotransmitter metabolism in spinal muscular atrophy

Understanding how SMN protein regulates the autophagy-lysosome pathway in spinal muscular atrophy

Posttranslational modifications of the Spinal Muscular Atrophy gene product SMN : Implications for therapy and pathophysiology

Recombinant SMN protein synergizes with spinal muscular atrophy therapy to counteract pathological motor neuron phenotypes

Spinal muscular atrophy

Enhancement of SMN protein levels in a mouse model of spinal muscular atrophy using novel drug‐like compounds

Calpain Inhibition Increases SMN Protein in Spinal Cord Motoneurons and Ameliorates the Spinal Muscular Atrophy Phenotype in Mice

The prevalence of SMN gene deletion/duplication in spinal muscular atrophy families referred to neuro-genetic centers of Mashhad, Iran

SMN

Absence of gemin5 from SMN complexes in nuclear Cajal bodies

VPAC2 receptor agonist BAY 55-9837 increases SMN protein levels and moderates disease phenotype in severe spinal muscular atrophy mouse models

Muscle contractility in spinobulbar muscular atrophy

SMN deficiency perturbs monoamine neurotransmitter metabolism in spinal muscular atrophy

Understanding how SMN protein regulates the autophagy-lysosome pathway in spinal muscular atrophy

Posttranslational modifications of the Spinal Muscular Atrophy gene product SMN : Implications for therapy and pathophysiology

Recombinant SMN protein synergizes with spinal muscular atrophy therapy to counteract pathological motor neuron phenotypes

Spinal muscular atrophy

Enhancement of SMN protein levels in a mouse model of spinal muscular atrophy using novel drug‐like compounds

Calpain Inhibition Increases SMN Protein in Spinal Cord Motoneurons and Ameliorates the Spinal Muscular Atrophy Phenotype in Mice

The prevalence of SMN gene deletion/duplication in spinal muscular atrophy families referred to neuro-genetic centers of Mashhad, Iran

SMN

Absence of gemin5 from SMN complexes in nuclear Cajal bodies

VPAC2 receptor agonist BAY 55-9837 increases SMN protein levels and moderates disease phenotype in severe spinal muscular atrophy mouse models

Muscle contractility in spinobulbar muscular atrophy

Related objects

Reset password